Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer

BJU International

Volumn 95, Issue 4, 2005, Pages 660-663

  Oka, Natsuo ^a   Yamamoto, Yasuyo ^a   Takahashi, Masayuki ^a   Nishitani, Masaaki ^a   Kanayama, Hiro Omi ^a   Kagawa, Susumu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

2; Angiogenesis; Angiopoietin 1; Bladder cancer; Immunohistochemistry; Prognosis

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CANCER STAGING; CANCER SURVIVAL; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; TUMOR GROWTH;

AGED; ANGIOPOIETIN-1; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 14644429809     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05358.x     Document Type: Article

References (21)

1. Schuster SJ, Koury ST, Bohler M, Salceda S, Caro J. Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. Br J Haematol 1992; 81: 153-9
2. Davis S, Aldrich TH, Jones PF et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-9
3. Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60
4. Wojchowski DM, Gregory RC, Miller CP, Pandit AK, Pircher TJ. Signal transduction in the erythropoietin receptor system. Exp Cell Res 1999; 253: 143-56
5. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-End CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 1995; 83: 59-67
6. Lin CS, Lim SK, D'Agati V, Costantini F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev 1996; 10: 154-64
7. Vogt C, Pentz S, Rich IN. A role for the macrophage in normal erythropoiesis. In vitro and in vivo erythropoietin gene expression in macrophages detected by in situ hybridization. Exp Hematol 1989; 17: 391-7
8. Eggert A, Ikegami N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000; 6: 1900-8
9. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M. Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma. Possible in vivo regulation via induction of proteases. Cancer Res 2001; 61: 2145-53
10. Peters KG. Vascular endothelial growth factor and the angiopoietins: working together to build a better blood vessel. Circ Res 1998; 83: 342-3
11. Suri C, Mclain J, Thurston G et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 282: 468-71
12. Papapertropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999; 79: 213-23
13. Sato TN, Tozawa Y, Deutsch U et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995; 376: 70-4
14. Dumont DJ, Gradwohl G, Fong GH et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994; 8: 1897-909
15. Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8
16. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998; 153: 1459-66
17. Takahama M, Tsutsumi M, Tsujiuchi T et al. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res 1999; 5: 2506-10
18. Wong MP, Chan SY, Fu KH et al. The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer 2000; 29: 11-22
19. Hatanaka H, Abe Y, Naruke M et al. Significant correlation between interleukin 10 expression and vascularization through angiopoietin/Tie2 networks in non-small cell lung cancer. Clin Cancer Res 2001; 7: 1287-92
20. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999; 103: 341-5
21. Ahmad SA, Liu W, Jung YD et al. Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. Cancer 2001; 92: 1138-43